Award-winning study ‘practice changing’ for severe aplastic anaemia

Adding the thrombopoietin receptor agonist eltrombopag (Revolade) to standard immunosuppressive treatment increases response rates in patients with Severe Aplastic Anaemia (SAA), preliminary results from the phase III RACE trial show. The trial (see abstract here), which was awarded the prestigious van Bekkum award at this year’s European Society for Blood and Marrow Transplantation virtual 46th ...

Already a member?

Login to keep reading.

© 2021 the limbic